Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone Open-Label Extension for MDD with Mixed Features
NCT01423253Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Sep 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lurasidone in major depressive disorder (MDD), sponsored by Sumitomo Pharma America. Primary endpoints: Treatment Emergent Adverse Events at 12 weeks, Treatment Emergent Serious Adverse Events at 12 weeks and 1 more. Started Sep 2011; status: completed.
02
Drugs
lurasidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01423253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01423253.